The international COMPASS project proposes that adding direct functional testing of drug sensitivities of patient-derived (PD) cancer cells to molecular profiling will provide additional key information for precision pediatric oncology.
The COMPASS consortium has four main aims: I) establish a standardized ex vivo drug response profiling platform to discover unexpected drug efficacies and drug re-positioning opportunities, II) discover new biomarkers and molecular mechanisms for the drug efficacies seen, III) generate a large-scale online data resource of drug efficacies with integrated omics data providing a basis for novel precision therapies for incurable pediatric tumors and IV) clinical translation. To achieve a high concordance in a multi-center setting, we will share standard operating procedures (SOP), a core set of genetically defined pediatric PD tumor models and a COMPASS core library containing clinically approved drugs.
Within the framework of the current project, Single-cell Technologies LLC provides software solutions for automatic, intelligent image analysis methods, involving automatic software development for analyzing image based 3D modeling, and the implementation of single cell technology.
| Project title: | Clinical implementation of Multidimensional Phenotypical drug Sensitivities in pediatric precision oncology (COMPASS) |
| Project number: | ED_18-1-2019-0017 |
| Project duration: | 01/07/2019-30/06/2022 |
| Project budget: | 133 493 750 Ft |
| Contracted amount: | 106 795 000 Ft |
| Extent of support: | 80 % |
| Name of recipient: | Single-cell Technologies LLC |